Applied Filters
The innovation paradox: why complex drug research is not being rewarded
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law.
Precision medicine: getting patenting spot on
Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson.
GQ Life Sciences: searching for sequence IP
The products made by GQ Life Sciences, based in Boston, make IP-related sequence searching easier for scientists, patent searchers and practitioners, as senior product manager Ellen Sherin tells LSIPR.
The quest for clarity continues
The English High Court is seeking answers from the CJEU on aspects of the EU’s regulation on supplementary protection certificates, but it’s possible questions will remain following the rulings. Michael Pears and Joel Beevers of Potter Clarkson report.
Enhanced damages: takeaways post-Halo
Almost one year after the US Supreme Court’s Halo decision, companies should consider a handful of best practices to reduce the risk of paying enhanced damages for wilful patent infringement, as Lynde Herzbach of Birch Stewart Kolasch Birch reports.
Advertising in Mexico: it pays to check your copy
An advice system for labelling products in Mexico has been extended to food and non-alcoholic beverages. Daniel Sanchez and Victor Ramirez of Olivares report on how the regime works in practice.
CRISPR in Europe: priority becomes just that at the EPO
The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains.
New framework for Spanish patentees
Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.
IP strategy: when sharing is caring
Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.
Bated breath: awaiting the Amgen v Sandoz verdict
With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry.
